Clin Exp Hypertens:如何选择降压药?单纯收缩压或舒张压高怎么办?

2017-12-08 沿若 医学论坛网

单药治疗高血压往往效果不好,需要几种降压药联合用药。还有很多老年人是单纯收缩压(高压)高,或者很多中青年单纯舒张压(低压)高,对此该如何选择降压药呢?


单药治疗高血压往往效果不好,需要几种降压药联合用药。还有很多老年人是单纯收缩压(高压)高,或者很多中青年单纯舒张压(低压)高,对此该如何选择降压药呢?

临床上,关于门诊血压(BP)的信息记录很少,在日常实践中最常见应用的是抗高血压药物组合治疗。哪种组合的降压效果好?williamhill asia 从联合两种到三种不同种属降压药组合治疗方案中寻找答案。
 
实验中,对17187名患者分成6组,分别以两种药物组合治疗;并对9724名患者分成6组,分别给以三种不同的药物组合治疗,他们的血压检测值被记录下来,对比了可获得的所有随机和动态血压值,随机血压目标控制范围(< 140/90 mmHg)和动态血压目标控制范围(24小时BP < 130/ 80;白日BP < 135/ 85,夜间BP < 120/70 mmHg)。
 
数据分析显示:

肾素-血管紧张素系统(RAS)受体阻滞剂与利尿剂两种药物组合、肾素-血管紧张素系统(RAS)受体阻滞剂、利尿剂和钙通道阻滞剂(CCB)的三重组合,可有效降低24小时动态血压低,尤其与降低夜间血压相关。与此两类组合相比,其他双种组合的降压效果甚微。此外,含有α受体阻滞剂的三重组合也显著的降压效果。
 
williamhill asia 得出结论,不同药物即使有相似的随机血压控制效果,在治疗期间,不同抗高血压药物组合之间存在一定差异,RAS阻滞剂/利尿剂组合和RAS阻断剂/ CCBs /利尿剂组合可获得更好的疗效。可以帮助临床医生在药物组合中选择用药,以获得更好的临床获益。

临床上常见的情况是,很多老年人是单纯收缩压(高压)高,或者很多中青年单纯舒张压(低压)高,对此该如何选择降压药呢?郭艺芳教授做了详细解释:
 
对于这一问题,现行的美国、欧洲、加拿大、日本以及中国等威廉亚洲博彩公司 性文件均未明确表述。但认真分析各威廉亚洲博彩公司 的推荐建议,仍然可以得到一些启示。单纯收缩压增高主要见于老年患者,而单纯舒张压增高常见于中青年患者。对于不同年龄阶段高血压患者的降压药物选择,相关威廉亚洲博彩公司 中有所描述。
 
2010版中国高血压防治威廉亚洲博彩公司 提到:对于舒张压<60mmHg的老年单纯收缩期高血压患者,若收缩压<150 mmHg可不用药;如收缩压150-179 mmHg,谨慎小剂量用药;如收缩压≥l80 mmHg,则小剂量用药,此时可选择小剂量利尿剂、CCB、ACEI或ARB,未推荐使用BB。
2013年加拿大高血压威廉亚洲博彩公司 认为:所有高血压患者均可考虑选用利尿剂、CCB、ACEI或ARB。60岁以下的患者(常伴舒张压增高)也可选择BB。单纯性收缩压增高者首先选用利尿剂、CCB或ARB。
 
2011年英国高血压威廉亚洲博彩公司 建议:55岁以下的高血压患者首选ACEI或ARB;55岁以上者首选CCB,不适于或不耐受CCB者则选用利尿剂。一般不建议将BB作为一线降压药物。然而,若年轻高血压患者不能耐受ACEI或ARB、或伴有交感张力增高表现者,可考虑选用BB。
 
其他权威威廉亚洲博彩公司 如2013年ESH/ESC威廉亚洲博彩公司 、2013年AHA/ACC/CDC威廉亚洲博彩公司 、2014ASH/ISH威廉亚洲博彩公司 、JNC8威廉亚洲博彩公司 以及2014年日本高血压威廉亚洲博彩公司 ,或未涉及此类话题,或提出了与上述威廉亚洲博彩公司 相似的观点。

由此可见,无论舒张压和(或)收缩压增高,利尿剂、CCB、ACEI、ARB均可考虑选用。对于以舒张压增高更为常见的年轻高血压患者,ACEI或ARB或可优先考虑选用;若年轻患者伴有交感张力增高表现(如心率快)且有心悸等不适症状,也可考虑选用BB,但需注意其对男性性功能的影响。对于收缩压增高更为常见的老年高血压患者,CCB或利尿剂可能更适于作为首选药物。
 
需要强调的是,无论收缩压增高还是舒张压增高,积极有效的生活方式干预均是必不可少的。对于单纯舒张压增高的中青年患者尤为如此。很多年轻高血压患者常伴有肥胖、酗酒、精神紧张等,限酒、减重是降低舒张压的有效措施。若整天大碗喝酒、大块吃肉、睡眠不足、不肯运动,什么药也不会有好的效果。

原始出处:

de la Sierra A1, Banegas JR2, Vinyoles E,et al.Office and ambulatory blood pressure control in hypertensive patients treated with different two-drug and three-drug combinations.Clin Exp Hypertens. 2016;38(4):409-14. doi: 10.3109/10641963.2016.1148160. Epub 2016 May 9.
 
 

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840317, encodeId=54bb184031eaf, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Sep 23 03:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726936, encodeId=ab001e2693645, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 21 20:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038791, encodeId=9fd02038e91f7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 21 05:48:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291943, encodeId=5b59129194354, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323097, encodeId=8b79132309eb8, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268076, encodeId=c1d22680e66b, content=生活方式与药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Dec 09 10:54:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840317, encodeId=54bb184031eaf, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Sep 23 03:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726936, encodeId=ab001e2693645, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 21 20:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038791, encodeId=9fd02038e91f7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 21 05:48:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291943, encodeId=5b59129194354, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323097, encodeId=8b79132309eb8, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268076, encodeId=c1d22680e66b, content=生活方式与药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Dec 09 10:54:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
    2018-10-21 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840317, encodeId=54bb184031eaf, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Sep 23 03:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726936, encodeId=ab001e2693645, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 21 20:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038791, encodeId=9fd02038e91f7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 21 05:48:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291943, encodeId=5b59129194354, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323097, encodeId=8b79132309eb8, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268076, encodeId=c1d22680e66b, content=生活方式与药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Dec 09 10:54:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840317, encodeId=54bb184031eaf, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Sep 23 03:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726936, encodeId=ab001e2693645, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 21 20:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038791, encodeId=9fd02038e91f7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 21 05:48:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291943, encodeId=5b59129194354, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323097, encodeId=8b79132309eb8, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268076, encodeId=c1d22680e66b, content=生活方式与药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Dec 09 10:54:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1840317, encodeId=54bb184031eaf, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Sep 23 03:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726936, encodeId=ab001e2693645, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 21 20:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038791, encodeId=9fd02038e91f7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 21 05:48:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291943, encodeId=5b59129194354, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323097, encodeId=8b79132309eb8, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268076, encodeId=c1d22680e66b, content=生活方式与药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Dec 09 10:54:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1840317, encodeId=54bb184031eaf, content=<a href='/topic/show?id=10905e20546' target=_blank style='color:#2F92EE;'>#收缩压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57205, encryptionId=10905e20546, topicName=收缩压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Sep 23 03:48:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726936, encodeId=ab001e2693645, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Oct 21 20:48:00 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038791, encodeId=9fd02038e91f7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 21 05:48:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291943, encodeId=5b59129194354, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323097, encodeId=8b79132309eb8, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 13:48:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268076, encodeId=c1d22680e66b, content=生活方式与药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Dec 09 10:54:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
    2017-12-09 lyh994

    生活方式与药物

    0

相关威廉亚洲官网

不是降压药却能引起低血压的药物

体循环动脉血压是血液在血管中流动时对血管壁的压力,是血液流动的动力。血压是血液循环流动的前提,血压在多种因素调节下保持正常,从而提供各组织器官以足够的血量,以维持正常的新陈代谢。血压有极其重要的生物学意义,过低过高都会造成严重后果。提到降血压,一般会想到降压药,除常规的降压药物外,很多药物也具有一定的心血管活性,可降低血压,不合理使用或可导致低血压事件发生,下面对这些药物进行归纳总结,方便临床参考

吃降压药有副作用,咋办?

1一些高血压患者服用降压药后可能会出现不适反应。遇到这种情况,一般不要自行停药,而是应该咨询医生,在医生指导下酌情处理。2这些不良反应有的是某种类型降压药所特有的副作用,也有的是血压降低所引起的。例如,一些平时血压很高但没有接受治疗的患者,服用降压药降低血压后可能会出现头晕、头痛、心慌、由坐位站起来时眼前发黑等。遇到这种情况一般不用停药,适当减小药物剂量后症状多可缓解。对于刚开始用药的患者,不要用

六类降压药:作用特点、临床选择和注意事项,全在这里!

临床工作中,经常遇到患者提出这样的疑问:这么多降压药,我该怎么使用?不只是患者不知道怎么用,一些非专科医生也可能不知道降压药的合理使用。前一段时间,曾经在我科住院的一个老年患者春节后回来复查,自诉春节期间和春节后血压特别高,无论怎么都控制不住。这个老爷子不到70岁,高血压20余年,近两年血压维持在180 mmHg左右,稍一激动就到200 mmHg。去年因双下肢水肿、血肌酐升高住院治疗,诊断为高

盘点:降压药近期又有啥重要研究发现?

高血压是一种以动脉血压持续升高为特征的进行性“心血管综合征”,常伴有其它危险因素、靶器官损害或临床疾患,需要进行综合干预。抗高血压治疗包括非药物和药物两种方法,大多数患者需长期、甚至终身坚持药物治疗,这里williamhill asia 小编整理了近期关于降压药的重要研究进展与大家一同分享。【1】降压药物晚间给药对CKD合并高血压患者BP模式有何影响2017年8月,发表在《Intern Med J》的一项系统评价和荟萃分析调查

Circ Cardiovasc Qual Outcomes:3种非专利降压药商业化对不良事件有何影响?

当专利药品的专利保护到期时,非专利药品生产商就能够合法地制作同样配方的药品,并以更便宜的价格出售。但非专利药物与专利药品完全等效吗?不良事件的发生率又会如何呢?2017年10月,发表在《Circ Cardiovasc Qual Outcomes》的一项基于人群的时间序列分析调查了3种非专利血管紧张素II受体阻滞剂氯沙坦、缬沙坦和坎地沙坦的商业化对不良事件的影响。